Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06210360 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Perioperative Treatment in High-risk Resectable Pancreatic Cancer With NALIRIFOX

StatusNot Yet Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated January 18, 2024 (before its estimated April 1, 2025 completion). Its status may not reflect the trial's current state.

Record History

  1. Study First Submitted
This multicentric randomized trial will compare the efficacy and safety of neoadjuvant chemotherapy + surgery + adjuvant chemotherapy or surgery + adjuvant chemotherapy in patients with high-risk resectable pancreatic cancer. NALIRIFOX (5-fluorouracil, leucovorin, irinotecan liposome injection and oxaliplatin) will be used as the chemotherapy regimen.
Trial Details
NCT Number NCT06210360
Lead Sponsor Changhai Hospital
Conditions
(from sponsor)		 Pancreatic Cancer
Related terms Pancreatic Neoplasms
Enrollment 134 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov